Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Scott McFarland

Physician Assistant Davenport, IA Physician Assistant

NPI 1902252463 CMS profile 1476155

3385 Dexter Ct Ste 300, Davenport, IA 52807

Open in the dashboard

General payments

$2,462

82 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott McFarland of Davenport, IA is reported in the CMS Open Payments database as having received $2,462 across 82 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $841 33
2024 General $822 25
2023 General $572 17
2022 General $77 5
2021 General $151 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott McFarland
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Scott McFarland were reported at $841. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Scott McFarland Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $151 $132 $37–$438 $132
2022 $77 $155 $48–$522 $149
2023 $572 $167 $52–$557 $160
2024 $822 $178 $55–$600 $164
2025 $841 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Stryker Corporation $1,717 49 payments
  2. Ferring Pharmaceuticals Inc. $379 23 payments
  3. Ethicon US, LLC $163 5 payments
  4. NuVasive, Inc. $125 1 payment
  5. Zimmer Biomet Holdings, Inc. $26 1 payment
  6. Pacira Pharmaceuticals Incorporated $24 1 payment
  7. Bioventus LLC $15 1 payment
  8. Innovation Technologies Inc $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,462 82 payments
Products named General payments · program years 2021–2025
  1. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $636 13 payments
  2. EUFLEXXA $379 23 payments
  3. AEQUALIS FLEX REVIVE $348 3 payments
  4. MAKO $290 6 payments
  5. TORNIER PERFORM REVERSED GLENOID $185 2 payments
  6. PROPHECY $155 8 payments
  7. XLIF $125 1 payment
  8. DERMABOND PRINEO $123 4 payments
  9. MOTIONSENSE DIGITAL GONIOMETER $89 1 payment
  10. AUGMENT INJECTABLE $43 3 payments
  11. Other $540 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

716

Median for Physician Assistant: 241

Drug cost

$6,401

Median for Physician Assistant: $4,110

Branded share of claims

11%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 127 $2,580
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 79 $1,008
Gabapentin Generic 119 $988
Oxycodone Hcl Generic 101 $713
Ondansetron Hcl Generic 97 $423
Cephalexin Generic 46 $226
Meloxicam Generic 58 $158
Methylprednisolone Generic 19 $122
Tramadol Hcl Generic 27 $96
Levofloxacin Generic 20 $70

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$11,447

Of which drugs: $2,250

Medicare patients

124

Average age 74

Services billed

522

70 women, 54 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Ischemic heart disease 27%
Diabetes 23%
Depression 23%
Chronic kidney disease 20%
COPD 15%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 45 217 $1,148

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record